Mylan offers discounts on EpiPen amid criticism
It is latest firm to be caught up in outrage at apparently egregious drug price increases
New York
MYLAN NV said on Thursday it would reduce the out-of-pocket costs of its emergency EpiPen allergy injection for some patients amid a wave of criticism from lawmakers and the public over the product's rapidly escalating price.
The list price of the drug will remain the same, but the company said it would increase the maximum copay assistance programme to US$300 from US$100 for patients who pay for the 2-pak in cash or who are covered by a commercial health insurer.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
AstraZeneca says it will withdraw Covid-19 vaccine globally as demand dips
UG Healthcare fully acquires German subsidiary for 16.9 million euros
Olam tops Louis Dreyfus’ offer for Australia’s Namoi Cotton as takeover battle heats up
Tiger Balm maker Haw Par should show its stripes, hunt for growth in alternative segments
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Australia’s retail sales volumes fall 0.4% in Q1